Datum Källa Rubrik Typ Alternativ
2024-04-19 Iconovo Kallelse till årsstämma i Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2024-03-20 Penser Access by Carnegie Penser Access by Carnegie: Iconovo - En ljus framtid Pressreleaser Visa Stäng
2024-03-11 Iconovo Iconovo presenterar positiva data från en feasibility-studie med Nanofitins® i ICOone® Pressreleaser Ladda ner | Visa Stäng
2024-03-11 Iconovo Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone® Pressreleaser Ladda ner | Visa Stäng
2024-03-06 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 6 mars 2024 Pressreleaser Ladda ner | Visa Stäng
2024-03-05 Iconovo Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea Pressreleaser Ladda ner | Visa Stäng
2024-03-05 Iconovo Iconovo erhåller anslag om SEK 680 000 från Innowwide för satsning på den Sydkoreanska marknaden Pressreleaser Ladda ner | Visa Stäng
2024-02-19 Redeye Redeye: Iconovo Q4 - Aligned with our expectations and a directed issue announcement Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo KVARTALSRAPPORT Rapporter Ladda ner | Visa Stäng
2024-02-15 Iconovo QUARTERLY REPORT Rapporter Ladda ner | Visa Stäng
2024-02-15 Iconovo Iconovo genomför riktad nyemission om 33,3 MSEK, delvis villkorad av efterföljande godkännande från extra bolagsstämma och tidigarelägger offentliggörande av bokslutskommunikén Pressreleaser Ladda ner | Visa Stäng
2024-02-15 Iconovo Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Iconovo BioStock: Iconovo inleder 2024 med order från ledande läkemedelsbolag Pressreleaser Visa Stäng
2024-02-07 Iconovo Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease Pressreleaser Ladda ner | Visa Stäng
2024-02-07 Iconovo Iconovo tecknar ytterligare avtal med Kiox Pharma för utveckling av en ny inhalerbar behandling av interstitiell lungsjukdom Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Iconovo Iconovo lanserar förbättrade versioner av nasala ICOone® inhalator Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Iconovo Iconovo launches improved versions of nasal ICOone® inhalers Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Iconovo Iconovo erhåller order från Top-10 Pharma-bolag för utvärdering av flerdosinhalator Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Iconovo Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Iconovo Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Iconovo Iconovo rekryterar Gary Pitcairn (PhD) som Senior Scientific Advisor Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Iconovo Iconovos vd till BioStock: "Vi siktar på en affär för ICOpre under 2024" Pressreleaser Visa Stäng
2023-12-06 Redeye Redeye: Redeye Initiates Coverage of Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Iconovo Iconovo AB byter likviditetsgarant och Certified Adviser till Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Iconovo Iconovo AB changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Iconovo Nomination Committee appointed at Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Iconovo Valberedning utsedd Iconovo AB Pressreleaser Ladda ner | Visa Stäng
2023-11-20 Iconovo BioStock: Busy days for Iconovo at BIO-Europe Pressreleaser Visa Stäng
2023-11-20 Iconovo BioStock: Hektiska dagar för Iconovo på BIO-Europe Pressreleaser Visa Stäng
2023-11-16 Iconovo Iconovo och Arcede Pharma tar nästa steg i utvecklingen av en ny behandling mot KOL Pressreleaser Ladda ner | Visa Stäng
2023-11-16 Iconovo Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD Pressreleaser Ladda ner | Visa Stäng
2023-10-31 Iconovo Iconovos styrelseledamot och medgrundare Mats Johansson förvärvar aktier för 2 039 388 SEK Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Penser Access Penser Access: Q3’23 - Iconovo Pressreleaser Visa Stäng
2023-10-27 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 27 oktober 2023 Pressreleaser Ladda ner | Visa Stäng
2023-10-27 Iconovo QUARTERLY REPORT Rapporter Ladda ner | Visa Stäng
2023-10-27 Iconovo KVARTALSRAPPORT Rapporter Ladda ner | Visa Stäng
2023-10-17 Iconovo Iconovos styrelse kommenterar att företagets vd åtalats för misstänkt marknadsmanipulation i annat bolags aktie Pressreleaser Ladda ner | Visa Stäng
2023-10-09 Iconovo BioStock: Iconovo welcomes Gerald Engström as largest shareholder through share issue Pressreleaser Visa Stäng
2023-10-09 Iconovo BioStock: Iconovo välkomnar Gerald Engström som huvudägare genom nyemission Pressreleaser Visa Stäng
2023-09-27 Iconovo BioStock Investor Meeting: Iconovo Pressreleaser Visa Stäng
2023-09-27 Iconovo BioStock Investor Meeting: Iconovo Pressreleaser Visa Stäng
2023-09-26 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo genomför riktad nyemission om cirka 19,2 MSEK Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo carries out a directed share issue of approx. SEK 19.2 million Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovo's partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-09-26 Iconovo Iconovos partner Monash University har slutfört rekryteringen till en klinisk fas I-studie av inhalerat oxytocin i ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Iconovo Iconovo beviljas ett amerikanskt patent för ICOcap® som stärker erbjudandet för att nå fler kundsamarbeten Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Iconovo Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Iconovo BioStock: Iconovo makes progress in the outlicensing process for ICOpre Pressreleaser Visa Stäng
2023-09-18 Iconovo BioStock: Iconovo gör framsteg i utlicenseringsprocessen för ICOpre Pressreleaser Visa Stäng
2023-09-13 Iconovo Iconovo inleder kontaktfasen i den strukturerade processen för att utlicensiera ICOpre Pressreleaser Ladda ner | Visa Stäng
2023-09-13 Iconovo Iconovo launches the outreach phase in the structured process for out-licensing of ICOpre Pressreleaser Ladda ner | Visa Stäng
2023-08-30 Iconovo Iconovos ny styrelseledamot förvärvar aktier för 204 373 SEK Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Iconovo Kommuniké från extra bolagsstämma i Iconovo AB den 28 augusti 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-23 Iconovo BioStock: Iconovo om vägen till lönsamhet Pressreleaser Visa Stäng
2023-08-23 Iconovo BioStock: Iconovo on the way to profitability Pressreleaser Visa Stäng
2023-08-22 Iconovo Iconovo stärker patentskyddet för ICOres® i EU Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Iconovo Iconovo strengthens patent protection for ICOres® in the EU Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Iconovo Iconovo receives additional development contract from Kiox Pharma for new inhalable treatment against rare disease Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Iconovo Iconovo får ytterligare utvecklingsuppdrag av Kiox Pharma gällande ny inhalerbar behandling mot sällsynt sjukdom Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Iconovo Iconovo confirms its long-term financial targets for 2027 with expected full-year profitability in 2026 Pressreleaser Ladda ner | Visa Stäng
2023-08-16 Iconovo Iconovo befäster sina långsiktiga finansiella mål för 2027, förväntad helårslönsamhet 2026 Pressreleaser Ladda ner | Visa Stäng
2023-08-09 Iconovo KALLELSE TILL EXTRA BOLAGSSTÄMMA I ICONOVO AB Pressreleaser Ladda ner | Visa Stäng
2023-07-17 Penser Access Penser Access: Q2 2023 - Iconovo Pressreleaser Visa Stäng
2023-07-14 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 14 juli 2023 Pressreleaser Visa Stäng
2023-07-14 Iconovo KVARTALSRAPPORT, Q2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-13 Iconovo Iconovo increases sales efforts and supply chain security for ICOcap through restructured agreement with Stevanato Pressreleaser Ladda ner | Visa Stäng
2023-07-13 Iconovo Iconovo ökar försäljningsinsatserna och säkrar produktionen för ICOcap genom omstrukturerat avtal med Stevanato Pressreleaser Ladda ner | Visa Stäng
2023-06-22 Iconovo BioStock: Iconovo ingår samarbete med Affilogic Pressreleaser Visa Stäng
2023-06-22 Iconovo BioStock: Iconovo initiates collaboration with Affilogic Pressreleaser Visa Stäng
2023-06-19 Iconovo Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies Pressreleaser Ladda ner | Visa Stäng
2023-06-19 Iconovo Iconovo inleder feasibility-studie med Affilogic för utveckling av inhalerbara Nanofitin®-baserade bioterapier Pressreleaser Ladda ner | Visa Stäng
2023-06-15 Iconovo BioStock: Iconovo launch Accelerator Program Pressreleaser Visa Stäng
2023-06-15 Iconovo BioStock: Iconovo lanserar Accelerator Program Pressreleaser Visa Stäng
2023-06-09 Iconovo Iconovo initiates collaboration with a small Danish company to develop a new inhalable treatment for a rare disease Pressreleaser Ladda ner | Visa Stäng
2023-06-09 Iconovo Iconovo inleder samarbete med danskt mindre bolag om utveckling av en ny inhalerbar behandling mot sällsynt sjukdom Pressreleaser Ladda ner | Visa Stäng
2023-06-01 Iconovo Iconovo provides increased opportunities for customers in its Novel Pharmaceuticals business segment to finance innovative development projects Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 1 Jun 2023 | Iconovo

Iconovo provides increased opportunities for customers in its Novel Pharmaceuticals business segment to finance innovative development projects

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the company strengthens its customer offering in the Novel Pharmaceuticals business segment by the launch of Iconovo Accelerator Program – a structured approach for pharmaceutical companies to obtain non-dilutive funding of commercially attractive projects. This is made possible through a newly established collaboration with the consulting firm Argentum, which specializes in structuring and managing application processes for EU funding and has so far helped secure over SEK 20 billion in research and development funding for its clients. The purpose of Iconovo Accelerator Program is to finance projects that are to a significant extent performed by Iconovo, which in turn can contribute to an increased earnings capacity for the company. Sales of medicines and vaccines for diseases where inhalers can provide significant benefits amount to almost USD 100 billion. Asthma, COPD, pulmonary hypertension and several types of vaccinations are some examples. Iconovo has already established four collaboration agreements in the Novel Pharmaceutical business segment, where it assists R&D-driven pharmaceutical companies in the development of completely new treatments based on the company’s unique proprietary inhalers.

There are however challenges in financing new innovative pharmaceutical projects, and many smaller companies lack access to expertise that can optimize opportunities to benefit from the substantial research grants awarded each year by the EU. Iconovo Accelerator Program is launched to offer customers strategic and operational support in connection with application processes for public funding of projects that are based on the company’s inhaler platforms.

”Many customers in our Novel Pharmaceuticals business segment request professional support in their processes for seeking EU funding to their development projects, and we are proud to have established a qualified process to accelerate the development of new inhalation products. By strengthening our customers’ financing capacity, we enhance the conditions for implementing collaborative projects in a time-efficient and professional manner. This in turn has potential to increase our earnings capacity,” says Johan Wäborg, CEO of Iconovo.

About Argentum
Argentum is a consultancy firm that specializes in optimizing the opportunities for its clients to obtain financial support for research projects from the EU. The company is part of the FreeMind Group, which has helped secure research and development funding of around EUR 2 billion for international clients since its inception in 1999.

2023-06-01 Iconovo Iconovo ökar möjligheterna för kunder inom affärsområdet originalläkemedel att finansiera innovativa utvecklingsprojekt Pressreleaser Ladda ner | Visa Stäng
2023-05-26 Iconovo Kommuniké från årsstämma i Iconovo AB den 22 maj 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-26 Iconovo BioStock: Iconovo inleder strukturerad säljprocess för ICOpre Pressreleaser Visa Stäng
2023-05-26 Iconovo BioStock: Iconovo initiates structured sales process for ICOpre Pressreleaser Visa Stäng
2023-05-23 Iconovo Carl Lindgren ny styrelseledamot i Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-05-23 Iconovo Carl Lindgren new board member of Iconovo Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Iconovo Iconovo inleder strukturerad process för utlicensiering av ICOpre i samarbete med global investmentbank Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Iconovo Iconovo initiates structured process for out-licensing of ICOpre with a global investment bank Pressreleaser Ladda ner | Visa Stäng
2023-05-15 Iconovo BioStock: Iconovo's oxytocin treatment in clinical phase I study Pressreleaser Visa Stäng
2023-05-15 Iconovo BioStock: Iconovos oxytocinbehandling i klinisk fas I-studie Pressreleaser Visa Stäng
2023-05-11 Iconovo Iconovos partner, Monash University har inlett en klinisk fas I-studie av inhalerat oxytocin i ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Iconovo Iconovo’s partner Monash University has initiated a phase I clinical trial on inhaled oxytocin in ICOone® Pressreleaser Ladda ner | Visa Stäng
2023-05-02 Penser Access Penser Access: Intervju med Iconovo - Erik Penser Bank - 2 maj 2023 Pressreleaser Visa Stäng
2023-05-02 Penser Access Penser Access: Avtal för ICOone - Iconovo Pressreleaser Visa Stäng
2023-04-28 Iconovo Rättelse: DELÅRSRAPPORT JANUARI - MARS 2023 Rapporter Ladda ner | Visa Stäng
2023-04-28 Iconovo Genomförd riktad emission på 55 MSEK stärker bolaget Rapporter Ladda ner | Visa Stäng
2023-04-28 Iconovo ICONOVO AB PUBLICERAR ÅRSREDOVISNING FÖR 2022 Rapporter Ladda ner | Visa Stäng

Kommande händelser

25 Apr 2024 | Kvartalsrapport 2024-Q1
17 May 2024 | Årligutdelning
12 Jul 2024 | Kvartalsrapport 2024-Q2
24 Oct 2024 | Kvartalsrapport 2024-Q3